Trial: 202109074

PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Phase

III

Principal Investigator

Baumann, Brian

Disease Site

Prostate

Learn more about this study at: clinicaltrials.gov